If you purchased the prescription acne medicine, Solodyn, in the US after July 23, 2009, you may be entitled to some form of compensation. A class action lawsuit claims that Medicis Pharmaceutical Corp. and Impax Laboratories (“Defendants”) unlawfully delayed the availability of allegedly less-expensive generic versions of Solodyn, causing consumers and third-parties to pay too much for the drug. The Defendants deny any wrongdoing. Those who purchased or paid for some or all of the purchase price for 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic versions in tablet form may become part of the End-Payor Class. The case is scheduled to go to trial on March 12, 2018 at the US District Court for the District of Massachusetts in Boston and additional information is available at www.SolodynCase.com.